注意缺陷多动障碍患者接受兴奋剂治疗后精神病与双相障碍的发生情况:系统综述与meta分析
结果显示,精神病症状发生比例为2.76%,精神病性障碍为2.29%,双相障碍为3.72%;苯丙胺类所致精神病风险显著高于哌甲酯(OR 1.57,95%CI 1.15-2.16)。作者指出研究无法确立因果关系,但临床应告知患者风险并系统监测。
要点
- ADHD患者使用兴奋剂后精神病症状发生比例2.76%,精神病性障碍2.29%,双相障碍3.72%。
- 苯丙胺类较哌甲酯精神病发生风险更高(OR 1.57,95%CI 1.15-2.16)。
- 临床处方兴奋剂时应告知精神病或双相障碍风险并系统监测。
核心结论
- ADHD患者接受兴奋剂治疗后精神病症状、精神病性障碍或双相障碍的发生并非可忽略。
- 苯丙胺类较哌甲酯与更高的精神病发生风险相关。
- 纳入研究无法确立因果关系,需进一步开展随机临床试验和镜像研究。
- 临床医生在讨论兴奋剂药物治疗时应告知患者精神病或双相障碍发生风险增加,并在治疗全程系统监测。
研究设计与样本
- 系统综述与meta分析,检索PubMed、Web of Science、Ovid/PsycINFO和Cochrane Central Register of Reviews,自建库至2024年10月1日,无语言限制。
- 纳入任何研究设计中经DSM或国际疾病分类定义ADHD人群暴露于兴奋剂并评估精神病或双相障碍结局的研究。
- 遵循PRISMA和MOOSE指南,方案已注册,使用Newcastle-Ottawa量表和Cochrane风险偏倚-2工具进行质量评价。
- 采用随机效应meta分析、亚组分析和meta回归。
主要发现
- 研究间异质性显著(I2>95%)。
关键数值与推荐
- 研究间异质性I2>95%。
临床怎么用
- 临床医生在讨论兴奋剂药物治疗时应告知患者精神病或双相障碍发生风险增加。
- 在兴奋剂治疗全程应系统监测精神病或双相障碍相关症状。
- 处方兴奋剂时需考虑药物类型(苯丙胺类vs哌甲酯)与精神病发生风险的关联。
局限性
- 纳入研究无法确立因果关系。
- 研究间异质性显著(I2>95%)。
- 需进一步开展随机临床试验和比较暴露与未暴露于兴奋剂的镜像研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Individuals with attention-deficit/hyperactivity disorder (ADHD) may present with psychosis or bipolar disorder (BD) following treatment with stimulants. The extent to which this occurs is currently unclear. OBJECTIVE: To meta-analytically quantify the occurrence of psychosis or BD after exposure to stimulants in individuals with ADHD and assess possible moderating factors. DATA SOURCES: PubMed, Web of Science, Ovid/PsycINFO, and Cochrane Central Register of Reviews were searched from inception until October 1, 2024, without language restrictions. STUDY SELECTION: Studies of any design with DSM or International Classification of Diseases-defined ADHD populations exposed to stimulants, where psychosis or BD outcomes were evaluated. DATA EXTRACTION AND SYNTHESIS: PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses and MOOSE Meta-analysis of Observational Studies in Epidemiology guidelines were followed, the protocol was registered, and the Newcastle-Ottawa scale and Cochrane risk of bias-2 tool were used for quality appraisal. Random-effects meta-analysis, subgroup analyses, and meta-regressions were conducted. MAIN OUTCOMES AND MEASURES: For the proportion of individuals developing psychotic symptoms, psychotic disorders, and BD, effect sizes are reported as percentages with 95% CIs. For the comparison between amphetamines and methylphenidate, effect sizes are presented as odds ratios with 95% CIs. RESULTS: Sixteen studies (N = 391 043; mean [range] age, 12.6 [8.5-31.1] years; 288 199 [73.7%] male) were eligible. Among individuals with ADHD prescribed stimulants, 2.76% (95% CI, 0.73-9.88; k = 10; n = 237 035), 2.29% (95% CI, 1.52-3.40; k = 4; n = 91 437), and 3.72% (95% CI, 0.77-16.05; k = 4; n = 92 945) developed psychotic symptoms, a psychotic disorder, and BD, respectively. Heterogeneity across the studies was significant (I2 > 95%). Psychosis occurrence risk was significantly higher in individuals exposed to amphetamines than to methylphenidate (odds ratio [OR], 1.57, 95% CI, 1.15-2.16; k = 3, n = 231 325). Subgroup analyses showed significantly higher prevalence of psychotic symptoms in studies from North America and in those with longer follow-up periods. Increased psychosis occurrence was associated with a higher proportion of female participants, smaller sample sizes, and higher dose of stimulants. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found a nonnegligible occurrence of psychotic symptoms, psychotic disorders, or BD in individuals with ADHD treated with stimulants. Amphetamines were associated with higher occurrence compared to methylphenidate. The included studies cannot establish causality, highlighting the need for further research, including randomized clinical trials and mirror-image studies comparing individuals exposed and not exposed to stimulants. Nonetheless, clinicians should inform patients about the increased occurrence of psychosis or BD when discussing stimulant pharmacotherapy and systematically monitor for these conditions throughout treatment.
引用
- Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40900605. doi:10.1001/jamapsychiatry.2025.2311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。